Advertisement

Drugs & Aging

, Volume 30, Issue 6, pp 439–445 | Cite as

Persistent use of Analgesic Medications in Mild-to-Moderate Alzheimer’s Disease

  • Adeline Gallini
  • Virginie Gardette
  • Bruno Vellas
  • Maryse Lapeyre-Mestre
  • Sandrine Andrieu
  • Christine Brefel-Courbon
  • the REAL.FR/DSA group
Original Research Article

Abstract

Background and Objectives

Previous studies have reported a lower use of analgesics in patients with Alzheimer’s disease (AD) than in non-AD elderly. To date, no study has focused on persistent analgesic use in patients with mild-to-moderate AD.

Methods

The “Réseau sur la maladie d’Alzheimer Français” (REAL.FR) cohort study enrolled community-dwelling patients with mild-to-moderate AD. Persistent analgesic use was defined as the consumption of at least one analgesic drug during two consecutive visits (6 months). Associated factors were identified in a nested case–control study.

Results

In REAL.FR, 595 patients were present during at least two consecutive visits [mean age = 77.5 ± 6.8 years, mini-mental state examination (MMSE) = 20.1 ± 4.2]. Prevalence of persistent analgesic use was 13.1 % (95 % CI = 10.4–15.9). The incidence of persistent analgesic use was 5.9/100 patient-years (95 % CI = 5.2–6.6). Women (adjusted odds ratio [OR] = 3.1, 95 % CI = 1.2–8.1), patients with musculoskeletal disorders (OR = 3.4, 95 % CI = 1.6–7.3) and patients treated with numerous medications (OR = 3.0, 95 % CI = 1.5–5.8) were more likely to use analgesics persistently. Statistically significant associations were found with disease duration and disease progression but not with AD severity at baseline.

Conclusions

Our results suggest a low use of analgesics in AD patients, which could vary with AD progression.

Keywords

Index Date Nursing Home Resident Clinical Dementia Rating Consecutive Visit Potential Adverse Drug Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The REAL.FR Study group refers to: Vellas B., Ousset PJ., Gillette-Guyonnet S., Nourhashemi F., Andrieu S. (Toulouse); Rainfray M., Richard-Harston S. (Bordeaux); Franco A., Couturier P. (Grenoble); Pasquier F., Mackowiak-Cordoliani M.A. (Lille); Frigard B., Idiri H., Gallouj K. (Wasquehal); Michel B. (Marseille); Jeandel Cl. (Montpellier); Touchon J., Portet F., Lerouge S. (Montpellier); Robert P., Brocker P., Bertogliati C. (Nice); Forette B., Teillet L., Lechowski L. (Paris); Belmin J., Pariel-Madjlelssi S. (Paris); Verny M., Artaz M.A. (Paris); Forette F., Rigaud A.S., Latour F. (Paris); Jouanny P., Belliard S., Michel O. (Rennes); Gonthier G., Girtanner C., Thomas-Anterion C. (Saint Etienne). The DSA group refers to: Andrieu S., Savy S., Cantet C., Coley N.

Funding

REAL.FR was supported by a grant from the French Ministry of Health (PHRC 98-47N and PHRC 18-05). Promotion of the REAL.FR study was supported by the University Hospital Centre of Toulouse. The data sharing activity was supported by the “Association Monegasque pour la recherche sur la maladie d’Alzheimer” (AMPA) and the UMR 1027 Unit INSERM – University of Toulouse III. The funding organizations were not involved in the design or conduct of the study, data collection, management, analysis or interpretation, nor in the preparation, review, or approval of the manuscript.

Transparency statement

The authors have no conflicts of interest relevant to the content of this study.

References

  1. 1.
    Scherder EJ, Bouma A. Is decreased use of analgesics in Alzheimer disease due to a change in the affective component of pain. Alzheimer Dis Assoc Disord. 1997;11(3):171–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Pickering G, Jourdan D, Dubray C. Acute versus chronic pain treatment in Alzheimer’s disease. Eur J Pain. 2006;10(4):379–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Bell JS, Laitinen M-L, Lavikainen P, et al. Use of strong opioids among community-dwelling persons with and without Alzheimer’s disease in Finland. Pain. 2011;152(3):543–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA. 1998;279(23):1877–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Closs SJ, Barr B, Briggs M. Cognitive status and analgesic provision in nursing home residents. Br J Gen Pract. 2004;54(509):919–21.PubMedGoogle Scholar
  6. 6.
    Feldt KS, Ryden MB, Miles S. Treatment of pain in cognitively impaired compared with cognitively intact older patients with hip-fracture. J Am Geriatr Soc. 1998;46(9):1079–85.PubMedGoogle Scholar
  7. 7.
    Horgas AL, Tsai PF. Analgesic drug prescription and use in cognitively impaired nursing home residents. Nurs Res. 1998;47(4):235–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Mäntyselkä P, Hartikainen S, Louhivuori-Laako K, et al. Effects of dementia on perceived daily pain in home-dwelling elderly people: a population-based study. Age Ageing. 2004;33(5):496–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Morrison RS, Siu AL. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. J Pain Symptom Manag. 2000;19(4):240–8.CrossRefGoogle Scholar
  10. 10.
    Nygaard HA, Jarland M. Are nursing home patients with dementia diagnosis at increased risk for inadequate pain treatment? Int J Geriatr Psychiatry. 2005;20(8):730–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Nygaard HA, Naik M, Ruths S, et al. Nursing-home residents and their drug use: a comparison between mentally intact and mentally impaired residents. The Bergen district nursing home (BEDNURS) study. Eur J Clin Pharmacol. 2003;59(5–6):463–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Parmelee PA, Smith B, Katz IR. Pain complaints and cognitive status among elderly institution residents. J Am Geriatr Soc. 1993;41(5):517–22.PubMedGoogle Scholar
  13. 13.
    Salles-Montaudon N, Fourrier A, Dartigues JF, et al. Evolution of drug treatments in the aged living at home. Rev Med Intern. 2000;21(8):664–71.CrossRefGoogle Scholar
  14. 14.
    Scherder E, Bouma A, Borkent M, et al. Alzheimer patients report less pain intensity and pain affect than non-demented elderly. Psychiatry. 1999;62(3):265–72.PubMedGoogle Scholar
  15. 15.
    Schmader KE, Hanlon JT, Fillenbaum GG, et al. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing. 1998;27(4):493–501.PubMedCrossRefGoogle Scholar
  16. 16.
    Zwakhalen SMG, Hamers JPH, Berger MPF. The psychometric quality and clinical usefulness of three pain assessment tools for elderly people with dementia. Pain. 2006;126(1–3):210–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Semla TP, Cohen D, Paveza G, et al. Drug use patterns of persons with Alzheimer’s disease and related disorders living in the community. J Am Geriatr Soc. 1993;41(4):408–13.PubMedGoogle Scholar
  18. 18.
    Hanlon JT, Fillenbaum GG, Studenski SA, et al. Factors associated with suboptimal analgesic use in community-dwelling elderly. Ann Pharmacother. 1996;30(7-8):739–44.PubMedGoogle Scholar
  19. 19.
    Lovheim H, Karlsson S, Gustafson Y. The use of central nervous system drugs and analgesics among very old people with and without dementia. Pharmacoepidemiol Drug Saf. 2008;17(9):912–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Scherder E, Oosterman J, Swaab D, et al. Recent developments in pain in dementia. BMJ. 2005;330(7489):461–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Scherder EJA, Sergeant JA, Swaab DF. Pain processing in dementia and its relation to neuropathology. Lancet Neurol. 2003;2(11):677–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Panel AGS. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46.CrossRefGoogle Scholar
  23. 23.
    Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. The REAL.FR research program on Alzheimer’s disease and its management: methods and preliminary results. J Nutr Health Aging. 2003;7(2):91–6.PubMedGoogle Scholar
  24. 24.
    American Psychiatric A. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  25. 25.
    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. A J Psychiatry. 1984;141(11):1356–64.Google Scholar
  28. 28.
    Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Brefel-Courbon C, Grolleau S, Thalamas C, et al. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain. 2009;141(1–2):14–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Methodology WHOCCfDS. ATC-DDD index. [cited 2012 March 6]. Available from: http://www.whocc.no/atc_ddd_index/.
  33. 33.
    Etminan M. Pharmacoepidemiology II: the nested case–control study—a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004;24(9):1105–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Scherder EJ. Low use of analgesics in Alzheimer’s disease: possible mechanisms. Psychiatry. 2000;63(1):1–12.Google Scholar
  36. 36.
    McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Br J Clin Pharmacol. 2011;71(3):351–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Marcum ZA, Perera S, Donohue JM, et al. Analgesic use for knee and hip osteoarthritis in community-dwelling elders. Pain Med. 2011;12(11):1628–36.PubMedCrossRefGoogle Scholar
  38. 38.
    Eggermont LH, Scherder EJ. Gender and analgesic use in nursing home residents with dementia. J Pain. 2008;9(10):970–1.PubMedCrossRefGoogle Scholar
  39. 39.
    Pokela N, Bell JS, Lihavainen K, et al. Analgesic use among community-dwelling people aged 75 years and older: a population-based interview study. Am J Geriatr Pharmacother. 2010;8(3):233–44.PubMedCrossRefGoogle Scholar
  40. 40.
    Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf. 2009;18(4):310–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Gardette V, Coley N, Toulza O, et al. Attrition in geriatric research: how important is it and how should it be dealt with? J Nutr Health Aging. 2007;11(3):265–71.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Adeline Gallini
    • 1
    • 2
    • 3
    • 8
  • Virginie Gardette
    • 1
    • 2
    • 3
    • 4
  • Bruno Vellas
    • 1
    • 2
    • 4
    • 5
  • Maryse Lapeyre-Mestre
    • 1
    • 2
    • 6
  • Sandrine Andrieu
    • 1
    • 2
    • 3
    • 4
  • Christine Brefel-Courbon
    • 2
    • 6
    • 7
  • the REAL.FR/DSA group
  1. 1.Inserm, UMR1027ToulouseFrance
  2. 2.Université de Toulouse IIIToulouseFrance
  3. 3.Service d’épidémiologieCHU de ToulouseToulouseFrance
  4. 4.GérontopôleCHU de ToulouseToulouseFrance
  5. 5.Service de Médecine interne et gérontologie cliniqueCHU de ToulouseToulouseFrance
  6. 6.Service de pharmacologie cliniqueCHU de ToulouseToulouseFrance
  7. 7.Inserm, UMR825ToulouseFrance
  8. 8.INSERM UMR 1027, Faculté de médecineUniversité de ToulouseToulouseFrance

Personalised recommendations